FDA Approves First Adjuvant Therapy for Renal Cell Carcinoma
The FDA has approved sunitinib malate (Sutent) as an adjuvant therapy for adults at risk for recurrent renal cell carcinoma following nephrectomy. Sunitinib, a kinase...
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Nephrectomy | Primary Care | Renal Cell Carcinoma